Literature DB >> 27316488

Circulating level of regulatory T cells in rheumatic heart disease: An observational study.

Saibal Mukhopadhyay1, Saurabh Varma2, H N Mohan Kumar3, Jamal Yusaf4, Mayank Goyal3, Vimal Mehta4, Sanjay Tyagi4.   

Abstract

BACKGROUND: The regulatory T cell (Treg) is essential for prevention of autoimmunity. In a preliminary study, we showed significant deficiency of Tregs (CD4CD25 T cells) in rheumatic heart disease (RHD) patients (an autoimmune disease), but the markers used could not reliably differentiate Treg from nonregulatory conventional T cells (Tcon). The study aim was to reassess the level of circulatory Tregs by using more specific markers.
METHODS: 70 adults of RHD and 35 controls were studied. Patients were subdivided according to the extent of left-sided valvular involvement. 35 patients with significant mitral-valve disease only were enrolled in the univalvular group while 35 patents with significant involvement of both mitral and aortic-valves in the multivalvular group. Circulating Treg cell level was determined by flow-cytometry.
RESULTS: Level of Tregs (CD4+CD25(med-high)CD127(low) Foxp3(high)) in CD4+ T lymphocyte was significantly lower in RHD patients compared to controls (median 0.6% versus 3.2%; p=0.001) with no significant difference in Tcon cells (p=0.94). Within the study group Treg count was significantly lower in patients with multivalvular-disease only (median 0.1% versus 3.2%; p=0.001) with no significant difference in Treg cell count between the univalvular group and control (median 1.9% versus 3.2%, p=0.10).
CONCLUSION: There is significant deficiency of circulating Tregs in patients of chronic RHD and the deficiency is greater in patients with multivalvular than univalvular involvement.
Copyright © 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Conventional T cell; Regulatory T cell; Rheumatic heart disease

Mesh:

Year:  2016        PMID: 27316488      PMCID: PMC4911432          DOI: 10.1016/j.ihj.2015.08.009

Source DB:  PubMed          Journal:  Indian Heart J        ISSN: 0019-4832


  29 in total

Review 1.  Rheumatic heart disease.

Authors:  Eloi Marijon; Mariana Mirabel; David S Celermajer; Xavier Jouven
Journal:  Lancet       Date:  2012-03-10       Impact factor: 79.321

Review 2.  Th17 and regulatory T cells in mediating and restraining inflammation.

Authors:  Dan R Littman; Alexander Y Rudensky
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

3.  Measurement of natural (CD4+CD25high) and inducible (CD4+IL-10+) regulatory T cells in patients with systemic lupus erythematosus.

Authors:  S Barath; M Aleksza; T Tarr; S Sipka; G Szegedi; E Kiss
Journal:  Lupus       Date:  2007       Impact factor: 2.911

Review 4.  Foxp3+ regulatory T cells: differentiation, specification, subphenotypes.

Authors:  Markus Feuerer; Jonathan A Hill; Diane Mathis; Christophe Benoist
Journal:  Nat Immunol       Date:  2009-07       Impact factor: 25.606

Review 5.  Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease.

Authors:  Bo Remenyi; Jonathan Carapetis; Rosemary Wyber; Kathryn Taubert; Bongani M Mayosi
Journal:  Nat Rev Cardiol       Date:  2013-04-02       Impact factor: 32.419

6.  Th17 and regulatory T cell subsets in diseases and clinical application.

Authors:  Huimin Fan; Zhongmin Liu; Shuiping Jiang
Journal:  Int Immunopharmacol       Date:  2011-02-24       Impact factor: 4.932

7.  Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab.

Authors:  E Toubi; A Kessel; Z Mahmudov; K Hallas; M Rozenbaum; I Rosner
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

8.  Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus.

Authors:  Jens Y Humrich; Henner Morbach; Reinmar Undeutsch; Philipp Enghard; Stefan Rosenberger; Olivia Weigert; Lutz Kloke; Juliane Heimann; Timo Gaber; Susan Brandenburg; Alexander Scheffold; Jochen Huehn; Andreas Radbruch; Gerd-Rüdiger Burmester; Gabriela Riemekasten
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

9.  Heart infiltrating T cell clones from a rheumatic heart disease patient display a common TCR usage and a degenerate antigen recognition pattern.

Authors:  K Faé; J Kalil; A Toubert; L Guilherme
Journal:  Mol Immunol       Date:  2004-02       Impact factor: 4.407

10.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.

Authors:  Weihong Liu; Amy L Putnam; Zhou Xu-Yu; Gregory L Szot; Michael R Lee; Shirley Zhu; Peter A Gottlieb; Philipp Kapranov; Thomas R Gingeras; Barbara Fazekas de St Groth; Carol Clayberger; David M Soper; Steven F Ziegler; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

View more
  5 in total

1.  Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1.

Authors:  Lora Hamuro; Giridhar S Tirucherai; Sean M Crawford; Akbar Nayeem; Renuka C Pillutla; Binodh S DeSilva; Tarek A Leil; Craig J Thalhauser
Journal:  AAPS J       Date:  2019-07-24       Impact factor: 4.009

Review 2.  T cell subsets: an integral component in pathogenesis of rheumatic heart disease.

Authors:  Devinder Toor; Neha Sharma
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

3.  Investigation on the Correlation between Serum Immune Factor Levels and Allergic Constitution in Children with Infectious Mononucleosis.

Authors:  Hong Sun; Weiqun Wang; Chenglei Lin; Min Chen
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-28       Impact factor: 2.629

4.  Evaluation of serum 25-hydroxyvitamin D levels in calcific rheumatic mitral stenosis- A cross sectional study.

Authors:  Jamal Yusuf; Jothinath P; Saibal Mukhopadhyay; Vickram Vignesh; Sanjay Tyagi
Journal:  Indian Heart J       Date:  2017-06-17

5.  The Binary Classification Of Chronic Diseases.

Authors:  Zeev Elkoshi
Journal:  J Inflamm Res       Date:  2019-12-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.